Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- SELF-MEDICATION NEWS IN BRIEF
June 2, 2008
- Kaken: Artz Drives 4.6% Increase in Sales
June 2, 2008
- MEDICAL DEVICE NEWS IN BRIEF
June 2, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 26, 2008
- All Univ. Hospitals Have Adopted Preminent: Banyu
May 26, 2008
- MEDICAL DEVICE NEWS IN BRIEF
May 26, 2008
- Janssen to Switch to Disease-based Marketing System
May 26, 2008
- Actos Inhibits CV Events in Diabetics: Takeda Seminar
May 26, 2008
- Shionogi to Emphasize Renal Protective Effect of Irbetan
May 26, 2008
- NEW PRODUCT
May 26, 2008
- Shionogi: Crestor Drives Sales and Profits
May 26, 2008
- REGULATORY NEWS IN BRIEF
May 26, 2008
- Taisho: Sales Up 4.7% for Ethical Drugs and 2.1% for Self-Medication
May 26, 2008
- R&D NEWS IN BRIEF
May 26, 2008
- Avapro Will Be 5th Strategic Product: DSP
May 26, 2008
- Use iPS Cells to Obtain Safety Data for NDA Submission
May 26, 2008
- MTPC Aims at Overseas Sales of \100 Bil. in FY2015
May 26, 2008
- Japan to Participate in Multinational PIII Study on VEGF Trap-Eye
May 26, 2008
- Eisai: First Deficit Reported due to Acquisition of MGI Pharma
May 26, 2008
- GENERICS NEWS IN BRIEF
May 26, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…